Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey.
Francesco SardanelliHildegunn S AaseMarina ÁlvarezEdward AzavedoHenk J BaarslagCorinne BalleyguierPascal A BaltzerVanesa BeslagicUlrich BickDragana Bogdanovic-StojanovicRuta BriedieneBoris BrkljacicJulia Camps HerreroCatherine ColinEleanor CornfordJan DanesGérard de GeerGul EsenAndrew EvansMichael H FuchsjaegerFiona J GilbertOswald GrafGormlaith HargadenThomas H HelbichSylvia H Heywang-KöbrunnerValentin IvanovÁsbjörn JónssonChristiane K KuhlEugenia C LisencuElzbieta LuczynskaRitse M MannJose C MarquesLaura MartincichMargarete MortierMarkus Müller-SchimpfleKatalin OrmandiPietro PanizzaFederica PediconiRuud M PijnappelKatja PinkerTarja RissanenNatalia RotaruGianni SaguattiTamar SellaJana SlobodníkováMaret TalkPatrice TaourelRubina M TrimboliIlse VejborgAthina VourtsisGabor ForraiPublished in: European radiology (2016)
• EUSOBI and 30 national breast radiology bodies support screening mammography. • A first priority is double-reading biennial mammography for women aged 50-69 years. • Extension to 73-75 and from 40-45 to 49 years is also encouraged. • Digital mammography (not film-screen or computer radiography) should be used. • DBT is set to become "routine mammography" in the screening setting in the next future.
Keyphrases
- contrast enhanced
- image quality
- artificial intelligence
- quality improvement
- magnetic resonance imaging
- magnetic resonance
- high resolution
- machine learning
- high throughput
- working memory
- metabolic syndrome
- clinical practice
- gold nanoparticles
- insulin resistance
- mass spectrometry
- skeletal muscle
- adipose tissue
- breast cancer risk
- reduced graphene oxide
- pregnancy outcomes